Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IlCatFrax

ABSTRACT: Catocala fraxini (Cliften non-pareil), genomic and transcriptomic data

PROVIDER: PRJEB50456 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR8373760_1.fastq.gz	Fastqsanger.gz
	ERR8373760_2.fastq.gz	Fastqsanger.gz
	ERR8373761_1.fastq.gz	Fastqsanger.gz
	ERR8373761_2.fastq.gz	Fastqsanger.gz
	ERR8373762_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

ilCatFrax

Project description:Catocala fraxini (Cliften non-pareil)

| PRJEB50461 | ENA

Catocala fraxini

Project description:Catocala fraxini overview

| PRJNA807042 | ENA

ilCatFrax1

Project description:Catocala fraxini (Cliften non-pareil) genome assembly, ilCatFrax1

| PRJEB50839 | ENA

ilCatSpon

Project description:Catocala sponsa, genomic and transcriptomic data

| PRJEB66397 | ENA

ilCatFrax1 alternate haplotype

Project description:Catocala fraxini (Cliften non-pareil) genome assembly, ilCatFrax1, alternate haplotype

| PRJEB50840 | ENA

ilCatNupt

Project description:Catocala nupta (red underwing), genomic and transcriptomic data

| PRJEB65728 | ENA

Liu2019 - Logistic Regression models to predict intrinsic resistance to anti-PD1 ICB in Ipilimumab treated and Ipilimumab naive patients with metastatic melanoma.

Project description:In this comprehensive study, the authors have developed concise models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 Immune Checkpoint Blockade (ICB) treatment in individual tumors. It's important to note that their validation was performed in smaller, independent cohorts, constrained by data availability. The authors have developed two Logistic Regression based models for Ipilimumab treated and Ipilimumab naive patients with metastatic melanoma. The main predictive features for the Ipilimumab treated patients are MHC-II HLA, LDH at treatment initiation and the presence of lymph node metastases (LN met), chosen using forward selection methodology. The main predictive features for the Ipilimumab naive patients are tumor heterogeneity, tumor ploidy and tumor purity, chosen using forward selection methodology. Please note that in these models, the output ‘1’ means progressive disease (PD) and ‘0’ means non-PD. The original GitHub repository can be accessed at https://github.com/vanallenlab/schadendorf-pd1

2023-11-17 | MODEL2310150001 | BioModels

ilCatSpon

Project description:Catocala sponsa

| PRJEB66398 | ENA

tfGorAlbo

Project description:Gordius_albopunctatus, genomic and transcriptomic data

| PRJEB78907 | ENA

Catocala nupta

Project description:Catocala nupta overview

| PRJNA1041546 | ENA